Lantus – said to be the most administered basal insulin across the world – continues to make blockbuster sales, bringing in almost $775 million for Sanofi in the first quarter of this year.

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

DiabetesMine explores how long a person with diabetes can live without insulin and how they can prolong life.

Meanwhile, the symptoms of type 2 diabetes develop more slowly than those of type 1 diabetes due to insulin resistance and the pancreas slowly losing the ability to produce enough insulin.